[go: up one dir, main page]

HK1016505A1 - 用於感染c型肝炎病患根除可檢測hcv-rna之結合治療 - Google Patents

用於感染c型肝炎病患根除可檢測hcv-rna之結合治療 Download PDF

Info

Publication number
HK1016505A1
HK1016505A1 HK99101676A HK99101676A HK1016505A1 HK 1016505 A1 HK1016505 A1 HK 1016505A1 HK 99101676 A HK99101676 A HK 99101676A HK 99101676 A HK99101676 A HK 99101676A HK 1016505 A1 HK1016505 A1 HK 1016505A1
Authority
HK
Hong Kong
Prior art keywords
interferon alpha
hcv
rna
interferon
patient
Prior art date
Application number
HK99101676A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1016505B (zh
Inventor
K. Albrecht Janice
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1016505(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK1016505A1 publication Critical patent/HK1016505A1/zh
Publication of HK1016505B publication Critical patent/HK1016505B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK99101676.1A 1997-09-21 1999-04-17 用於感染c型肝炎病患根除可检测hcv-rna之结合治疗 HK1016505B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US938033 1997-09-21
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22
US935123 2001-08-21

Publications (2)

Publication Number Publication Date
HK1016505A1 true HK1016505A1 (zh) 1999-11-05
HK1016505B HK1016505B (zh) 2002-02-08

Family

ID=

Also Published As

Publication number Publication date
WO1999015194A1 (en) 1999-04-01
HUP0100092A2 (hu) 2001-05-28
PT903148E (pt) 2002-02-28
HUP0100092A3 (en) 2002-03-28
EP1317929A3 (en) 2003-07-02
PE119199A1 (es) 1999-12-01
EP0903148B1 (en) 2001-10-10
DK1136075T3 (da) 2003-04-28
CO4970691A1 (es) 2000-11-07
CA2245938C (en) 2003-07-15
CN1271292A (zh) 2000-10-25
MY117781A (en) 2004-08-30
KR20010024188A (ko) 2001-03-26
AU749924B2 (en) 2002-07-04
AR013497A1 (es) 2000-12-27
TW568787B (en) 2004-01-01
EP1317929A2 (en) 2003-06-11
DE69801970D1 (de) 2001-11-15
AU9473798A (en) 1999-04-12
DE69810822D1 (de) 2003-02-20
ATE230999T1 (de) 2003-02-15
NO20001437L (no) 2000-03-20
BR9812484A (pt) 2000-09-19
EP1136075A1 (en) 2001-09-26
IL134428A0 (en) 2001-04-30
EP1136075B1 (en) 2003-01-15
ES2186660T3 (es) 2003-05-16
NO20001437D0 (no) 2000-03-20
CN1250283C (zh) 2006-04-12
HK1041440B (zh) 2003-09-05
NZ502740A (en) 2002-10-25
CA2245938A1 (en) 1999-03-21
EP0903148A3 (en) 1999-04-28
EP0903148A2 (en) 1999-03-24
JPH11152231A (ja) 1999-06-08
DE69801970T2 (de) 2002-06-13
DK0903148T3 (da) 2001-12-17
ATE206618T1 (de) 2001-10-15
HK1041440A1 (zh) 2002-07-12
SK3922000A3 (en) 2000-10-09
ES2162393T3 (es) 2001-12-16
DE69810822T2 (de) 2003-11-20

Similar Documents

Publication Publication Date Title
EP0903148B1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6172046B1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP0956861B1 (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
US6472373B1 (en) Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US20020127203A1 (en) Ribavirin-pegylated interferon alfa HCV combination therapy
EP1140143A2 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en) Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037097A1 (en) Ribavirin-interferon alfa induction hcv combination therapy
HK1016505B (zh) 用於感染c型肝炎病患根除可检测hcv-rna之结合治疗
HK1056837A (zh) 用於清除慢性丙型肝炎病毒感染患者体内的可检测的hcv-rna的联合治疗
AU2005218024A1 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
HK1021131B (zh) 用於带有C型肝炎感染之抗病毒治疗不生效用的病人之包含有瑞巴维林(RIBAVIRIN)与干扰素α的组合疗法
HK1044464A (zh) 用於根除具有慢性丙型肝炎感染的抗病毒治疗原发患者中的可测的hcv-rna的组合治疗
HK1154495A (zh) 用於清除從未接受抗病毒治療的慢性丙肝感染患者的可檢測的hcv-rna的結合療法
MXPA98007284A (en) Combination therapy to eradicate vhc-rna detectable in patients who have infection of hepatitis c cron
CZ2000788A3 (cs) Použití ribavirinu pro výrobu farmaceutických prostředků, použití interferonů alfa pro výrobu farmaceutických prostředků a farmaceutické výrobky

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070807